Clinical Trial

Anti-GD2 ADC M3554 in Advanced Solid Tumors

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to establish the recommended doses and further evaluate the safety and preliminary antitumor activity of M3554 in participants with soft tissue sarcoma (STS) and glioblastoma, IDH-wildtype. Study details include: Study Duration per participant: Approximately 4 months
Protocol Amendment History 1 change
notable Primary completion pushed: 2026-10-27 -> 2027-04-16 2026-04-16
Trial Details
NCT Number NCT06641908
Lead Sponsor EMD Serono Research & Development Institute, Inc.
Collaborators: Merck KGaA, Darmstadt, Germany
Conditions Advanced Solid Tumor
Enrollment 52 participants
Start Date 2024-11-08
Primary Completion 2027-04-16 (estimated)
Study Completion 2027-04-16 (estimated)
Updated on ClinicalTrials.gov 2026-08-12